Compare ESRT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | SLDB |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 834.5M | 781.7M |
| IPO Year | 2012 | 2017 |
| Metric | ESRT | SLDB |
|---|---|---|
| Price | $4.63 | $5.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $5.20 | ★ $18.71 |
| AVG Volume (30 Days) | ★ 4.8M | 1.4M |
| Earning Date | 11-02-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,270,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $3.93 | $3.79 |
| 52 Week High | $8.04 | $11.45 |
| Indicator | ESRT | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 24.03 |
| Support Level | $3.95 | $5.52 |
| Resistance Level | $5.85 | $7.42 |
| Average True Range (ATR) | 0.16 | 0.36 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 69.43 | 10.71 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.